FDA Agrees to Fast Track Potential Cystic Fibrosis Therapy, QR-010, Now Under Clinical Testing

ProQR Therapeutics announced that QR-010, an inhaled therapy it is developing to treat cystic fibrosis patients with the ∆F508 mutation in the CFTR gene (the gene that is defective in CF), has received Fast Track designation from the U.S. Food and Drug Administration (FDA) to speed its testing and review. The drug is now being…

Investigational Cystic Fibrosis Drug QR-010 to be Explored in Two Trials; Enrollment is Now

ProQR Therapeutics is set to release results from a study on the effect of the investigational drug QR-010 on nasal potential difference – an evaluation of CFTR protein function in patients with cystic fibrosis (CF). The findings will be presented at the North American Cystic Fibrosis Conference (NACFC), Oct. 27…